Growth fraction of tumour cells and infiltration density with natural killer-like (HNK1+) cells in non-Hodgkin lymphomas.

Greil R, Gattringer C, Knapp W, Huber H. Br J Haematol. 1986 Feb,62(2):293-300.

In situ quantification of T-cell subsets, NK-like cells and macrophages in Hodgkin’s disease: quantity and quality of infiltration density depends on histopathological subtypes.

Gattringer G, Greil R, Radaszkiewicz T, Huber H. Blut. 1986 Jul,53(1):49-58.

[Studies of immunologic markers in malignant lymphomas: diagnostic and prognostic relevance].

Huber H, Thaler J, Greil R, Gattringer C, Radaszkiewicz T. Onkologie. 1986 Apr,9(2):108-13.

Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactions.

Schulz TF, Vogetseder W, Mitterer M, Neumayer HP, Myones BL, Stauder R, Greil R, Böck G, Feichtinger H, Huber H, et al. Mol Immunol. 1988 Nov,25(11):1053-61.

Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour.

Stauder R, Greil R, Schulz TF, Thaler J, Gattringer C, Radaskiewicz T, Dierich MP, Huber H. Clin Exp Immunol. 1989 Aug,77(2):234-8.

Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin.

Thaler J, Denz H, Dietze O, Gastl G, Ho AD, Gattringer C, Greil R, Lechleitner M, Huber C, Huber H. Leuk Res. 1989,13(5):377-83.

Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.

El Kababji S, Mitsakakis N, Jonker E, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow W, Gralow J, Savard MF, Fesl C, Hlauschek D, Balic M, Rinnerthaler G, Greil R, Gnant M, Clemons M, El Emam K. J Med Internet Res. 2025 Mar 5;27:e66821. doi: 10.2196/66821. PMID: 40053790.